DOCSLIB.ORG

Comparison of Monocyte-Dependent T Cell Inhibitory Activity in GM- CSF Vs G-CSF Mobilized PSC Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of Monocyte-Dependent T Cell Inhibitory Activity in GM- CSF Vs G-CSF Mobilized PSC Products Bone Marrow Transplantation, (1999) 23, 63–69 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comparison of monocyte-dependent T cell inhibitory activity in GM- CSF vs G-CSF mobilized PSC products AG Ageitos1, ML Varney1, PJ Bierman2, JM Vose2, PI Warkentin1 and JE Talmadge1 1Department of Pathology and Microbiology, and 2Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA Summary: following transplant compared to normal individuals. PSCT patients, however, have a more rapid immune recovery than This study compares the immune properties of periph- do BMT patients.5–7,10 eral blood stem cell (PSC) products mobilized with dif- Stem cells are mobilized from the bone marrow (BM) ferent hematopoietic growth factors (HGFs) as well as into the peripheral blood (PB) after myelosuppressive apheresis products and peripheral blood leukocytes chemotherapy,12 chemotherapy combined with HGFs13–17 (PBL) from normal individuals. We found that mono- or during administration of HGFs.18–24 Accelerated hemato- cytes in mobilized PSC products appear to inhibit T cell poietic recovery is observed following PSCT as compared function independent of whether granulocyte colony- to transplantation with steady-state BM and is only stimulating factor (G-CSF) or granulocyte–macrophage observed when peripheral blood stem cell (PSC) products colony-stimulating factor (GM-CSF) was used for mobi- are collected after mobilization.21,24,25 The choice of HGF lization. In addition, the GF used to mobilize the stem used for mobilization may also be important as granulo- cell product may be less important to the CD4:CD8 cyte–macrophage colony-stimulating factor (GM-CSF) ratio than the extent of prior chemotherapy, as we interacts with earlier progenitors than does granulocyte found an inverse correlation between chemotherapy and colony-stimulating factor (G-CSF)26 and increases the fre- the CD4:CD8 ratio. In other observations, all apheresis quency of granulocytes, macrophages, eosinophils, mega- products, whether mobilized or unmobilized, contained karyocytes, erythroid precursors, and dendritic cells from significantly more monocytes compared to normal PBL. hematopoietic progenitors.27 In addition, the administration The mononuclear cells (MNC) from G-CSF or GM-CSF of GM-CSF28 or G-CSF29 after autologous BMT or PSCT mobilized PSC products had a similar T cell phytohem- also can enhance the endogenous cytotoxic and antimicro- agglutinin (PHA) mitogenic response that was signifi- bial30 activity of immune cells. cantly lower (P = 0.001 and P = 0.005, respectively) than G-CSF is used most frequently for mobilization and has non-mobilized apheresis products. We also examined been shown to enhance the production and maturation of neu- the T cell inhibitor (TI) activity of the MNC from the trophils in vitro and in vivo.27,31,32 G-CSF is unique among PSC products for allogeneic lymphocyte proliferation the regulators of granulopoiesis in that it not only stimulates and found that PSC products significantly reduced the the proliferation, but also induces the terminal maturation of proliferation of allogeneic PBL to PHA. A significant myeloid progenitor cells.33 Like other cytokines, G-CSF correlation (P = 0.001, r = 0.517) between the frequency exerts a pleiotropic effect on different cell populations. The of monocytes and TI activity also was observed. G-CSF receptor can be found on myeloid progenitor cells, Keywords: monocytes; stem cell mobilization; T cells; mature neutrophils, platelets, monocytes, and some T and B GM-CSF; G-CSF lymphoid cell lines.33 In addition, the PSC pool can be expanded by both G-CSF and GM-CSF.34–36 While it is well documented that the injection of HGFs mobilizes stem cells with different hematopoietic properties dependent on the The therapeutic efficacy of hematopoietic growth factor HGF, no studies to date have compared the immunologic (HGF) administration has been shown in a variety of dis- characteristics of PSC products mobilized with different 1,2 eases. One such utility includes rapid myelorestoration HGFs. following high-dose chemotherapy (HDT) and stem cell Analysis of G-CSF mobilized PSC products has shown transplantation. Although peripheral blood stem cell trans- that they contain at least three times more T cells than plantation (PSCT) has largely replaced bone marrow trans- steady-state BM products. However, the frequency of natu- plantation (BMT) due to a lower incidence of tumor-cell ral killer (NK) and T cells in these PSC products is in the 3 4–6 contamination and more rapid hematopoietic recovery, range expected for normal PB.37 We and others have 5–11 both BMT and PSCT patients are immunosuppressed reported9,38 that GM-CSF mobilized PSC products have a high frequency of monocytes. Furthermore, the phenotypic analysis of mobilized PSC products revealed normal levels Correspondence: Dr JE Talmadge, Department of Pathology and Micro- + + biology, University of Nebraska Medical Center, 600 South 42nd Street, of CD4 cells and an increased frequency of CD8 cells, Omaha, NE 68198-5660, USA which results in a decreased CD4:CD8 cell ratio as com- Received 29 May 1998; accepted 11 August 1998 pared to the PB of normal individuals. Monocytes in PSC products AG Ageitos et al 64 While the effects of GM-CSF and G-CSF on myeloid Isolated mononuclear cells (MNC) cells have been studied, the effect of HGF mobilization on lymphoid cells is not well understood. GM-CSF has been MNC were obtained from apheresis products and the hep- reported to amplify interleukin (IL)-2 supporting T cell pro- arinized venous blood of 49 normal donors by Ficoll– liferation,39 and in patients with non-Hodgkin’s lymphoma Hypaque gradient centrifugation. The interphase cells were (NHL), there is an increase in the absolute lymphocyte harvested, washed three times in Hanks’ balanced salt sol- count, particularly activated lymphocytes after GM-CSF ution (HBSS; Life Technologies; Gaithersburg, MD, USA), 40 41 and resuspended in RPMI-1640 medium supplemented with administration. Other reports have examined the ability ␮ of GM-CSF to induce T cell proliferation and found that 1mm HEPES, glutamine, 40 g/ml gentamycin (Life it upregulated the expression of IL-2 receptors on T lym- Technologies), and 10% fetal bovine serum (FBS). phocytes. We report here a comparison of the effect of G- CSF and GM-CSF mobilization on lymphocyte and mono- Proliferation assay cyte function and phenotype in PSC products. Phytohemagglutinin (PHA)-induced T cell proliferation was measured by determining 3H-thymidine incorporation into DNA. Cells (100 ␮l/well) were plated in quadruplicate Materials and methods in flat-bottomed wells of microtiter plates at 1 × 106 cells/ml. The cells were cultured in PHA (100 ␮l/well) at Patients and control group a final concentration of 0.5 ␮g/ml of media. On day 3, the ␮ 3 A total of 54 apheresis products, including HGF mobilized wells were pulsed for 18 h with 1 Ci of H-thymidine leukapheresis products from 36 patients and 18 non-mobil- (Amersham Life Sciences; Arlington Heights, IL, USA) ized apheresis products from healthy donors, were exam- and the cells harvested on day 4 using an automatic multi- ined. The samples were divided into three groups, accord- well harvester (Packard Instruments, Downers Grove, IL, ing to whether HGF was used for mobilization and whether USA). The filters were allowed to air dry, scintillation G-CSF or GM-CSF was used for mobilization. PSC apher- cocktail was added, and the samples were counted in a esis products were collected from 21 patients following Packard multi-well beta-plate counter. In all studies, a con- GM-CSF and from 15 patients following G-CSF mobiliz- trol of normal peripheral blood leukocytes (PBL) was ation. NHL patients who were eligible for PSCT at the Uni- included and the data are reported as the percent of the versity of Nebraska Medical Center (UNMC) were entered control sample. into these studies. The samples were obtained using proto- cols approved by the Institutional Review Board of UNMC Flow cytometry and following written informed consent. The clinical characteristics of both groups are shown in Table 1. Using Flow cytometric analyses were used for the phenotyping the same protocol as for the cancer patients, non-mobilized, studies. The cell populations were studied prior to Ficoll– apheresis products were obtained from normal donors and Hypaque separation and erythrocytes removed by lysis. Ali- served as a control group for the mobilized PSC apheresis. quots of 5 × 104 cells were stained with biotin-conjugated monoclonal antibodies (MoAb) to CD8 and CD14, a fluor- escein isothiocyanate (FITC)-labeled MoAb to CD3, and a phycoerythrin (PE)-labeled MoAb to CD4. After incubation Table 1 Characteristics of study patients and washing, streptavidin allophycocyanin (APC) was added as the third fluorochrome. The data were acquired Clinical features G-CSF GM-CSF on a FACStarPlus using a 40 mw, 488 nm argon laser and mobilized mobilized a 100 mW, 647 nm HeNe laser for excitation. Detailed data analysis was performed using Paint-A-Gate Plus software Number 15 21 Sex from Becton Dickinson (San Jose, CA, USA). Male 7 9 Female 8 12 Age (years) T cell inhibition assay Median 48 45 Range 27–64 14–63 The coculture assay used to measure the cellular inhibition Prior therapy of T cell function has been described previously.9,38,42,43 Chemotherapy 15 21 Briefly, Ficoll–Hypaque purified, normal PBL (1 × 105)as Radiation 6 responder cells were cocultured with varying numbers of Months of chemotherapy median 2 9a irradiated (500 cGy) putative inhibitor cells (MNC from PB range 1–5 2–25 or PSC product) starting at an inhibitor to responder ratio Tumor type (I:R) of 4:1. Four, two-fold dilutions of inhibitor cells (50 Non-Hodgkin’s lymphoma 15 16 ␮l) were made in 96-well flat bottom plates.
Load more

Recommended publications
  • Pearls of Laboratory Medicine Transcript Document
    Pearls of Laboratory Medicine www.traineecouncil.org TITLE: Transfusion Support in Hematopoietic Stem Cell Transplant PRESENTER: Erin K. Meyer, DO, MPH Slide 1: Title Slide Hello, my name is Erin Meyer. I am the medical director of apheresis and associate medical director of Transfusion Services at Nationwide Children’s Hospital in Columbus Ohio. Welcome to this Pearl of Laboratory Medicine on “Transfusion Support in Hematopoietic Stem Cell Transplant or HSCT.” Slide 2: Transfusion Support for Hematopoietic Stem Cell Transplant (HSCT) The objectives of my talk are a brief overview of the different types of HSCT followed by a review of the sources of HSCT available and transfusion thresholds for patients receiving the different types of HSCT. Finally, I will discuss ABO-incompatible HSCT with a focus on the complications of and transfusion support for each possible ABO-incompatible combination. Hematopoietic stem cells came to light after the dropping of the atomic bombs in 1945. People who survived the initial explosions later died of bone marrow failure from radiation. A series of sentinel experiments by Till and McCulloch in the 1960s then showed that transfer of bone marrow cells from donor mice into lethally irradiated recipient mice resulted in the formation of colonies of myeloid, erythroid, and megakaryocytic cells in the recipient’s spleen approximately 7-14 days later. Stem cells have two very unique properties: the ability to self-renew and the ability to regenerate. The field of stem cell biology has only grown and HSCTs are able to be transplanted now to recipients to help a variety of diseases.
    [Show full text]
  • Hematopoietic Stem Cell Therapy) in MS
    FAQ About HSCT (Hematopoietic Stem Cell Therapy) in MS There is growing evidence that autologous HSCT is not for everyone with MS but may be highly effective for people with relapsing MS who meet very specific characteristics. The National Medical Advisory Committee of the National MS Society has written an article reviewing evidence related to the optimal use of autologous hematopoietic stem cell transplantation (aHSCT, commonly known as bone marrow transplants) for the treatment of specific types of relapsing multiple sclerosis. The committee’s findings are published in JAMA Neurology (online October 26, 2020). Q. What is HSCT for multiple sclerosis? A. HSCT (Hematopoietic Stem Cell Transplantation) attempts to “reboot” the immune system, which is responsible for damaging the brain and spinal cord in MS. In HSCT for MS, hematopoietic (blood cell-producing) stem cells, which are derived from a person’s own (“autologous”) bone marrow or blood, are collected and stored, and the rest of the individual’s immune cells are depleted by chemotherapy. Then the stored hematopoietic stem cells are reintroduced to the body. The new stem cells migrate to the bone marrow and over time produce new white blood cells. Eventually they repopulate the body with immune cells. Q. What is the idea behind autologous HSCT (aHSCT) for MS? A. The goal of aHSCT is to reset the immune system and stop the inflammation that contributes to active relapsing MS. Q. Is aHSCT an FDA-approved therapy option for people with MS? A. The medications and procedures used in aHSCT are already approved by the FDA. Publication of the outcomes from well-controlled clinical studies of aHSCT therapy will encourage greater acceptance and use by the medical community.
    [Show full text]
  • IDF Guide to Hematopoietic Stem Cell Transplantation
    Guide to Hematopoietic Stem Cell Transplantation Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation This publication contains general medical information that cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this publication should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. Copyright 2018 by Immune Deficiency Foundation, USA Readers may redistribute this guide to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation (IDF). If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA, or by telephone: 800-296-4433. For more information about IDF, go to: www.primaryimmune.org. This publication has been made possible through the IDF SCID Initiative and the SCID, Angels for Life Foundation. Acknowledgements The Immune Deficiency Foundation would like to thank the organizations and individuals who helped make this publication possible and contributed to the development of the Immune Deficiency Foundation Guide to Hematopoietic Stem
    [Show full text]
  • Stem Cell Hematopoiesis
    Hematopoietic and Lymphoid Neoplasm Project Introduction to the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 4th edition 2 Hematopoietic and Lymphoid Lineages, Part I Steven Peace, CTR Westat September 2009 3 Objectives • Understand stem cell hematopoiesis • Understand proliferation • Understand differentiation • Provide a History of Classification of Tumors of Hematopoietic and Lymphoid Tissues • Understand the delineation of cell lines (lineage) in relation to the WHO Classification 4 Objectives (2) • Introduce WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed. • Introduce NEW ICD-O histology codes • Introduce NEW reportable conditions 5 Stem Cell Hematopoiesis • What is a hematopoietic stem cell? • Where are hematopoietic stem cells found? • What is Hematopoiesis? • Hematopoietic stem cells give rise to ALL blood cell types including; • Myeloid lineages • Lymphoid lineages 6 Hematopoietic stem cells give rise to two major progenitor cell lineages, myeloid and lymphoid progenitors Regenerative Medicine, 2006. http://www.dentalarticles.com/images/hematopoiesis.png 7 Proliferation and Differentiation • Regulation of proliferation • Regulation of differentiation • Both affect development along cell line • Turn on/Turn off • Growth factors • Genes (including mutations) • Proteins • Ongogenesis – becoming malignant 8 Blood Lines – Donald Metcalf, AlphaMED Press, 2005 Figure 3.2 The eight major hematopoietic lineages generated by self-renewing multipotential stem cellsB Copyright © 2008 by AlphaMed
    [Show full text]
  • Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S
    bioRxiv preprint doi: https://doi.org/10.1101/503813; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S. Stumpf2,†, Yoshiko M. Ikushima3,†, Kentaro Hosokawa1, Aline Roch4, Matthias P. Lutolf4, Toshio Suda5, and Ben D. MacArthur2,6,7,* †† 1Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, 812-8582, Fukuoka, Japan. 2Centre for Human Development, Stem Cells and Regeneration, University of Southampton, SO17 1BJ, UK 3Research Institute National Center for Global Health and Medicine, Tokyo, Japan 4Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland 5Cancer Science Institute, National University of Singapore, 14 Medical Drive, MD6, 117599 Singapore, Singapore 6Institute for Life Sciences, University of Southampton, SO17 1BJ, United Kingdom 7Mathematical Sciences, University of Southampton, SO17 1BJ, United Kingdom *Correspondence to Fumio Arai ([email protected]) and Ben MacArthur ([email protected]) †These authors contributed equally. ††Lead Author ABSTRACT Loss of stem cell self-renewal may underpin aging. Here, we combined single cell profiling, deep-learning, mathematical modelling and in vivo functional studies to explore how hematopoietic stem cell (HSC) division patterns evolve with age. We trained an artificial neural network (ANN) to accurately identify cell types in the hematopoietic hierarchy and predict their age from their gene expression patterns.
    [Show full text]
  • Differential Contributions of Haematopoietic Stem Cells to Foetal and Adult Haematopoiesis: Insights from Functional Analysis of Transcriptional Regulators
    Oncogene (2007) 26, 6750–6765 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators C Pina and T Enver MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK An increasing number of molecules have been identified ment and appropriate differentiation down the various as candidate regulators of stem cell fates through their lineages. involvement in leukaemia or via post-genomic gene dis- In the adult organism, HSC give rise to differentiated covery approaches.A full understanding of the function progeny following a series of relatively well-defined steps of these molecules requires (1) detailed knowledge of during the course of which cells lose proliferative the gene networks in which they participate and (2) an potential and multilineage differentiation capacity and appreciation of how these networks vary as cells progress progressively acquire characteristics of terminally differ- through the haematopoietic cell hierarchy.An additional entiated mature cells (reviewed in Kondo et al., 2003). layer of complexity is added by the occurrence of different As depicted in Figure 1, the more primitive cells in the haematopoietic cell hierarchies at different stages of haematopoietic differentiation hierarchy are long-term ontogeny.Beyond these issues of cell context dependence, repopulating HSC (LT-HSC),
    [Show full text]
  • Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S
    Knowledge of transfusion complications related to HSCT can help with the early detection and treatment of patients before and after transplantation. Ray Paul. SP12-6796 × 40, 2013. Acrylic, latex, enamel on canvas printed with an image of myxofibrosarcoma with metastases to the artist’s lung, 26" × 36". Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S. Cohn, MD, PhD Background: Patients receiving hematopoietic stem cell transplantation require extensive transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable complications may arise when the transplanted stem cells are incompatible with the native ABO type of the patient. Immediate and delayed hemolysis is often seen. Methods: A literature review was performed and the results from peer-reviewed papers that contained reproducible findings were integrated. Results: A strong body of clinical evidence has developed around the common complications experienced with ABO-incompatible hematopoietic stem cell transplantation. These complications are discussed and the underlying pathophysiology is explained. General treatment options and guidelines are enumerated. Conclusions: ABO-incompatible hematopoietic stem cell transplantations are frequently performed. Immune-related hemolysis is a commonly encountered complication; therefore, health care professionals must recognize the signs of immune-mediated hemolysis and understand the various etiologies that may drive the process. Introduction antigen (HLA) matching remains an important predic- Hematopoietic stem cell transplantation (HSCT) is used tor of success with HSCT; however, the ABO barrier is to treat a variety of hematological and congenital diseas- often crossed when searching for the most appropriate es. The duration and specificity of transfusion support HLA match between donor and patient.
    [Show full text]
  • Stem-Cell Transplant Acute Myeloid Leukemia, 11A-2
    NC Medicaid Medicaid and Health Choice Hematopoietic Stem-Cell Clinical Coverage Policy No: 11A-2 Transplantation for Amended Date: July 1, 2021 Acute Myeloid Leukemia (AML) To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after implementation, please contact your PHP. Table of Contents 1.0 Description of the Procedure, Product, or Service ........................................................................... 1 1.1 Definitions .......................................................................................................................... 4 1.1.1 Donor Lymphocyte Infusion (DLI) ....................................................................... 4 2.0 Eligibility Requirements .................................................................................................................. 4 2.1 Provisions............................................................................................................................ 4 2.1.1 General ................................................................................................................... 4 2.1.2 Specific .................................................................................................................. 5 2.2 Special Provisions ............................................................................................................... 5 2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age ......................................................................
    [Show full text]
  • Quiescence and Self-Renewal Hematopoietic Stem Cell Status
    The Endothelial Antigen ESAM Monitors Hematopoietic Stem Cell Status between Quiescence and Self-Renewal This information is current as Takao Sudo, Takafumi Yokota, Kenji Oritani, Yusuke of October 2, 2021. Satoh, Tatsuki Sugiyama, Tatsuro Ishida, Hirohiko Shibayama, Sachiko Ezoe, Natsuko Fujita, Hirokazu Tanaka, Tetsuo Maeda, Takashi Nagasawa and Yuzuru Kanakura J Immunol 2012; 189:200-210; Prepublished online 30 May 2012; doi: 10.4049/jimmunol.1200056 Downloaded from http://www.jimmunol.org/content/189/1/200 Supplementary http://www.jimmunol.org/content/suppl/2012/05/30/jimmunol.120005 http://www.jimmunol.org/ Material 6.DC1 References This article cites 57 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/189/1/200.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American
    [Show full text]
  • The Number of Nucleated Cells Reflects the Hematopoietic Content of Umbilical Cord Blood for Transplantation
    Bone Marrow Transplantation, (1999) 24, 965–970 1999 Stockton Press All rights reserved 0268–3369/99 $15.00 http://www.stockton-press.co.uk/bmt The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation FTH Lim1,2, JM v Beckhoven3, A Brand3, JC Kluin-Nelemans1, JMH Hermans4, R Willemze1, HHH Kanhai2 and JHF Falkenburg1 Departments of 1Hematology, 2Obstetrics and 4Medical Statistics from the Leiden University Medical Center; and 3Red Cross Blood Bank, Leidsenhage, The Netherlands Summary: irradiated recipients. Since the colony-forming unit granulocyte–monocyte (CFU-GM) defined in a semi-solid A single umbilical cord blood (UCB) collection may con- culture assay, has been associated with hematopoietic tain sufficient hematopoietic stem cells to achieve engraftment of human bone marrow cells, this assay has engraftment and repopulation of the hematopoietic sys- been used as a quality control method for hematopoietic tem of children and adults after myeloablative therapy. stem cell grafts.12,13 The hematopoietic potential of a UCB unit is often The human hematopoietic stem cells reside in the frac- defined by the number of CD34+ cells or the number of tion of cells expressing the CD34 antigen.14,15 CD34+ cells colony-forming units as measured in semisolid hemato- can be identified by flow cytometry, but the various tech- poietic progenitor cell (HPC) cultures. However, these niques for CD34 enumeration that have been advocated assays are relatively difficult to standardize between may result in different estimated concentrations.16–18 Both UCB banks. The number of nucleated cells infused per the CD34+ cell content, and the numbers of hematopoietic kilogram body weight of the recipient is also reported progenitor cells (HPC) as determined in semi-solid medium to be a significant factor in the speed of recovery of culture assays are frequently used to predict the hematopoi- neutrophils and platelets after transplantation.
    [Show full text]
  • Hematopoiesis Hematopoietic Stem Cells in Adult AML1/Runx1 Negatively Regulates Quiescent
    AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis This information is current as Motoshi Ichikawa, Susumu Goyama, Takashi Asai, Masahito of September 28, 2021. Kawazu, Masahiro Nakagawa, Masataka Takeshita, Shigeru Chiba, Seishi Ogawa and Mineo Kurokawa J Immunol 2008; 180:4402-4408; ; doi: 10.4049/jimmunol.180.7.4402 http://www.jimmunol.org/content/180/7/4402 Downloaded from References This article cites 37 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/180/7/4402.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis1 Motoshi Ichikawa, Susumu Goyama, Takashi Asai, Masahito Kawazu, Masahiro Nakagawa, Masataka Takeshita, Shigeru Chiba, Seishi Ogawa, and Mineo Kurokawa2 Transcription factor AML1/Runx1, initially isolated from the t(8;21) chromosomal translocation in human leukemia, is essential for the development of multilineage hematopoiesis in mouse embryos.
    [Show full text]
  • Hematopoietic Developmental Pathways: on Cellular Basis
    Oncogene (2007) 26, 6687–6696 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Hematopoietic developmental pathways: on cellular basis H Iwasaki1 and K Akashi1,2 1Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan and 2Department of Cancer Immunology and AIDS, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA To elucidate the molecular mechanisms underlying normal counterpart, the common myeloid progenitor (CMP) and malignant hematopoietic development, it is critical to that can be a source of all myeloid cell types, supports identify developmental intermediates for each lineage the concept that lymphoid and myeloid lineages develop downstream of hematopoietic stem cells. Recent advances independently downstream of HSCs (Kondo et al., 1997; in prospective isolation of hematopoietic stem and Akashi et al., 2000). progenitor cells, and efficient xenogeneic transplantation Recent progresses in the fluorescence-activated cell systems have provided a detailed developmental map in sorting analysis using additional surface markers for both mouse and human hematopoiesis, demonstrating that early hematopoiesis, however, have provided more surface phenotypes of mouse stem–progenitor cells and detailed developmental map downstream of HSCs. their human counterparts are considerably different. Importantly, prior to proceed into the classical myeloid Here, we summarize the phenotype and functional vs lymphoid pathways, HSCs appear to form myelo- properties and their differences of hematopoietic stem erythroid vs myelo-lymphoid progenitors (Arinobu and progenitor cell populations between mouse and et al., 2007). Furthermore, it is now clear that there human. are considerable differences in distribution of surface Oncogene (2007) 26, 6687–6696; doi:10.1038/sj.onc.1210754 markers between human and mouse hematopoiesis, which makes identification of human counterparts of Keywords: hematopoietic stem cell; lineage commitment; mouse progenitors difficult.
    [Show full text]